Table 2 Diagnoses and treatments received
Description | N | % | Missing n (%) |
|---|---|---|---|
Diagnoses | 1 (0.3%) | ||
Ductal Carcinoma In Situ (DCIS) | 33 | 10.7% | |
Localised breast cancer | 252 | 81.8% | |
Metastatic breast cancer | 14 | 4.6% | |
Inflammatory breast cancer | <5 | 0.7% | |
Other including second primary | 7 | 2.3% | |
Treatment to the Breast | 2 (0.6%) | ||
Lumpectomy alone | <5 | 0.7% | |
Lumpectomy and radiation | 129 | 42.0% | |
Mastectomy alone | 74 | 24.1% | |
Mastectomy and radiation | 71 | 23.1% | |
Lumpectomy and mastectomy alone | 10 | 3.3% | |
Lumpectomy, mastectomy and radiation | 16 | 5.2% | |
Double mastectomy | 5 | 1.6% | |
Reconstruction after mastectomy (n = 164) | |||
No | 84 | 51.2% | |
Immediate | 37 | 22.6% | |
Delayed | 43 | 26.2% | |
Treatment to the Axilla (n = 167) | 13 (7.8%) | ||
Sentinel node biopsy only | 24 | 15.6% | |
Axillary dissection +/− Sentinel node biopsy | 56 | 36.4% | |
Axillary dissection +/− Sentinel node biopsy + radiation | 72 | 46.8% | |
Radiation only | <5 | 1.3% | |
Intravenous Systemic Therapy | |||
Chemotherapy without Herceptin | 164 | 53.1% | |
Herceptin only | < 5 | 0.7% | |
Chemotherapy + Herceptin | 46 | 14.9% | |
None/not reported | 97 | 31.4% | |
Hormonal Treatments | |||
Tamoxifen alone | 58 | 18.8% | |
Other | 146 | 47.3% | |
None | 105 | 34.0% | |
Current use of hormone therapy | |||
Yes | 125 | 40.5% | |